Differences in Patient-Physician Satisfaction for Migraine Treatment Medications in Patients with and without Medication-Overuse Headache: A Cross-Sectional Real-World Survey
Authors:
- Ryotaro IshiiRIRyotaro Ishii
- Takahiro KitanoTKTakahiro Kitano
- Masahiro IijimaMIMasahiro Iijima
- Mitsuhiro NaganoMNMitsuhiro Nagano
- Reiko YoshikawaRYReiko Yoshikawa
- James JacksonJJJames Jackson
- Sophie BarlowSBSophie Barlow
- Emily GreenEGEmily Green
- William WhittonWWWilliam Whitton
- Lucy HargreavesLHLucy Hargreaves
- Kanae TogoKTKanae Togo
Open Access
- 19 August 2025
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (5) , 1-23
Abstract
Introduction Medication overuse headache (MOH) is incurred by the excessive use of acute medications, including over-the-counter (OTC) treatments. This study aimed to characterize the burden, management, and treatment satisfaction of patients with migraine with or without MOH in Japan. Methods Data were derived from the Adelphi Migraine Disease Specific Programme (DSP)™, a cross-sectional survey conducted in Japan from August 2023 to February 2024. Physicians provided data for consecutive patients, including demographics, clinical characteristics, current treatment, OTC treatment usage, and treatment satisfaction. Patients voluntarily reported their symptom burden, migraine pain severity, and treatment satisfaction. Alignment between physician and patient regarding treatment satisfaction was assessed using Cohen’s weighted kappa statistics and multivariable regression models. Results Overall, 122 physicians provided data for 820 patients with migraine, 7.0% (n = 57) of whom had a diagnosis of MOH; 41.5% (n = 340) of patients self-reported data, with 3.2% (n = 11) having a diagnosis of MOH. Patients with MOH were more likely to experience chronic migraine (79%, n = 45), greater migraine frequency, and more severe migraine than those without MOH. Ninety percent of both groups received acute treatment. Patients with MOH were significantly more likely to receive preventive treatment than those without MOH (86% vs 56.6%, p < 0.001). OTC medication use was reported at 3.3% by physicians and 11.2% by patients. The alignment between physician and patient treatment satisfaction was low for acute treatment. The exploratory model analysis indicated that OTC use may have contributed to this misalignment. Conclusion Our study revealed that the alignment regarding treatment satisfaction with acute medications is low. OTC treatment usage may have inflated physician satisfaction with prescribed acute medications and caused a discrepancy regarding satisfaction of patients with MOH. To improve patient outcomes, it is essential to align drug effectiveness ratings between physicians and patients by enhancing communication and mutual understanding.Keywords
Funding Information
- Pfizer Japan
This publication has 41 references indexed in Scilit:
- Defining the Differences Between Episodic Migraine and Chronic MigraineCurrent Pain and Headache Reports, 2011
- Chronic migraine plus medication overuse headache: two entities or not?The Journal of Headache and Pain, 2011
- Treatment of medication overuse headache - guideline of the EFNS headache panelEuropean Journal of Neurology, 2011
- Validity and Reliability of the Migraine-Treatment Optimization QuestionnaireCephalalgia, 2009
- Medication-Overuse Headache in JapanCephalalgia, 2008
- Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understandCurrent Medical Research and Opinion, 2008
- Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disabilityNeurology, 2001
- Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferersPain, 2000
- An international study to assess reliability of the Migraine Disability Assessment (MIDAS) scoreNeurology, 1999
- The Measurement of Observer Agreement for Categorical DataBiometrics, 1977